ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Comparison of zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV)

Comparison of zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV)
Vaccine Efficacy (incidence HZ) Systemic side effects that prevented normal everyday activities (vaccine versus placebo) Follow-up Comment
ZVL (single dose) Population ≥60 years of age[1]:
51% reduction in risk of HZ compared with placebo (95% CI 44.2-57.6%; 11.12 versus 5.42 per 1000 person-years)		 <1% reported in post-hoc analysis[5] 3.1 years

Vaccine efficacy was significantly greater in individuals aged 60 to 69 years compared with those ≥70 years (63.9 versus 37.6%). Protection against postherpetic neuralgia was 67%[1].

Observational studies found the protection from ZVL wanes significantly after 5 to 8 years (from approximately 50% to 20 to 30% for those ≥60 years of age)[6-8]. Protection against postherpetic neuralgia was maintained significantly longer.
Population 50 to 59 years of age[2]:
70% reduction in risk of HZ compared with placebo (95% CI 54.1-80.6%; 6.57 versus 1.99 per 1000 person-years)		 1.3 years
RZV (2 doses separated by 2 months) Population ≥70 years of age[3]:
89% reduction in risk of HZ compared with placebo (95% CI 84.2-93.7%; 9.2 versus 0.9 per 1000 person-years)		 6 versus 2% 3.7 years

Myalgia was the most common systemic reaction.

Protection against postherpetic neuralgia in patients ≥70 years of age was 89%.
Population ≥50 years of age[4]:
96.2% reduction in risk of HZ compared with placebo (95% CI 92.7-98.3%; 9.1 versus 0.3 per 1000 person-years)		 11.4 versus 2.4% 3.2 years
RZV: recombinant zoster vaccine; ZVL: zoster live vaccine; HZ: herpes zoster.
References:
  1. Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.
  2. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922.
  3. Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375:1019.
  4. Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087.
  5. Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety profile of a herpes zoster Vaccine. A Detailed Review of Data from CSP #403: the Shingles Prevention Study. Ann Intern Med 2010; 152:545.
  6. Baxter R, Bartlett J, Fireman B, et al. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. Am J Epidemiol 2018; 187:161.
  7. Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60:900.
  8. Tseng HF, Harpaz R, Luo Y, et al. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years. J Infect Dis 2016; 213:1872.
Graphic 116904 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟